DE69127437T2 - Stickoxide zur gewichtsreduktion - Google Patents

Stickoxide zur gewichtsreduktion

Info

Publication number
DE69127437T2
DE69127437T2 DE69127437T DE69127437T DE69127437T2 DE 69127437 T2 DE69127437 T2 DE 69127437T2 DE 69127437 T DE69127437 T DE 69127437T DE 69127437 T DE69127437 T DE 69127437T DE 69127437 T2 DE69127437 T2 DE 69127437T2
Authority
DE
Germany
Prior art keywords
nitroxes
weight reduction
oxazolidine
oxyls
nitroxides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69127437T
Other languages
English (en)
Other versions
DE69127437D1 (de
Inventor
James Mitchell
William Degraff
Stephen Hahn
Amram Samuni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
US Department of Commerce
Original Assignee
US Department of Health and Human Services
US Department of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, US Department of Commerce filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69127437D1 publication Critical patent/DE69127437D1/de
Publication of DE69127437T2 publication Critical patent/DE69127437T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Dental Preparations (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Paper (AREA)
DE69127437T 1990-03-16 1991-03-18 Stickoxide zur gewichtsreduktion Expired - Lifetime DE69127437T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49453290A 1990-03-16 1990-03-16
PCT/US1991/001778 WO1991013619A1 (en) 1990-03-16 1991-03-18 Nitroxides as protectors against oxidative stress

Publications (2)

Publication Number Publication Date
DE69127437D1 DE69127437D1 (de) 1997-10-02
DE69127437T2 true DE69127437T2 (de) 1998-02-05

Family

ID=23964864

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69133313T Expired - Lifetime DE69133313T2 (de) 1990-03-16 1991-03-18 Verwendung von Nitroxiden und Oxazolidinen zum Schutz ionisierender Strahlung und oxidativem Stress
DE69127437T Expired - Lifetime DE69127437T2 (de) 1990-03-16 1991-03-18 Stickoxide zur gewichtsreduktion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69133313T Expired - Lifetime DE69133313T2 (de) 1990-03-16 1991-03-18 Verwendung von Nitroxiden und Oxazolidinen zum Schutz ionisierender Strahlung und oxidativem Stress

Country Status (10)

Country Link
US (1) US5462946A (de)
EP (2) EP0520005B1 (de)
JP (1) JP2741427B2 (de)
AT (2) ATE249829T1 (de)
AU (1) AU644865B2 (de)
CA (1) CA2078287C (de)
DE (2) DE69133313T2 (de)
DK (1) DK0787492T3 (de)
ES (1) ES2207690T3 (de)
WO (1) WO1991013619A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714482A (en) * 1985-07-18 1998-02-03 Proctor; Peter H. Topical spin labels and method
US5728714A (en) * 1985-07-18 1998-03-17 Proctor; Peter H. Method for treating hair loss using tempo
US5714510A (en) * 1985-07-18 1998-02-03 Proctor; Peter H. Topical proxyl composition and method
US6605619B1 (en) * 1992-03-20 2003-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxides as protectors against oxidatives stress
US5840701A (en) * 1993-08-16 1998-11-24 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
TW381022B (en) * 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5767089A (en) * 1993-08-16 1998-06-16 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5817632A (en) * 1993-08-16 1998-10-06 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5804561A (en) * 1993-08-16 1998-09-08 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5824781A (en) * 1993-08-16 1998-10-20 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5725839A (en) * 1993-08-16 1998-03-10 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
US5807831A (en) * 1993-08-16 1998-09-15 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5741893A (en) * 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US6716858B1 (en) 1995-08-28 2004-04-06 Kansas University Medical Center Methods for inhibiting diabetic complications
US6001853A (en) * 1996-01-26 1999-12-14 The United States Of America As Represented By The Department Of Health And Human Services Hydroxylamine compositions for the prevention or retardation of cataracts
JP2000511516A (ja) * 1996-05-07 2000-09-05 エリック・エフ・バーンスタイン 光加齢（ｐｈｏｔｏａｇｉｎｇ）予防におけるテンポルの使用
US6096759A (en) 1997-09-19 2000-08-01 Georgetown University Method for treating essential hypertension
ATE367809T1 (de) 1998-04-21 2007-08-15 Us Health Cannabinoiden als antioxidantien und neuroschützende mittel
AU5817099A (en) 1998-09-09 2000-03-27 Baker Hughes Incorporated Vinyl monomer polymerization inhibition using hindered hydroxylamines
JP2003502372A (ja) * 1999-06-23 2003-01-21 エリック・エフ・バーンスタイン 創傷治癒および光傷害の防止におけるニトロキシドの使用
WO2002026231A1 (en) * 2000-09-26 2002-04-04 Georgetown University Use of nitroxides for the treatment of vascular disorders in a diabetic mammal
US20030045461A1 (en) * 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
US20040219201A1 (en) * 2001-12-06 2004-11-04 Yechezkel Barenholz Tempamine compositions and methods of use
EP1507826A4 (de) * 2002-05-17 2007-11-07 Othera Pharmaceuticals Inc Verbesserung der entwicklung von katarakten und anderen augenerkrankungen
EP1553945A4 (de) * 2002-10-01 2008-11-05 Mitos Pharmaceuticals Inc Nitroxid-strahlenschutzformulierungen und anwendungsverfahren
JP2006524701A (ja) * 2003-04-25 2006-11-02 ミトス・インコーポレーテッド 酸化防止剤による予防的前処置
US7589107B2 (en) 2003-05-19 2009-09-15 Othera Holding, Inc. Amelioration of vitrectomy-induced cataracts
US7825134B2 (en) * 2003-05-19 2010-11-02 Othera Holding, Inc. Amelioration of cataracts, macular degeneration and other ophthalmic diseases
AU2004243004A1 (en) * 2003-05-29 2004-12-09 Mitos Pharmaceuticals, Inc. Methods of using nitroxides in conjunction with photosensitizers and sonosensitizers
WO2005037213A2 (en) * 2003-10-14 2005-04-28 Cornell Research Foundation, Inc. Antiinflammatory inhibitors of respiratory burst in adherent neutrophils
US7285544B2 (en) * 2003-11-18 2007-10-23 Bernstein Eric F Use of nitroxides in treating skin disease
AU2004293105B2 (en) * 2003-11-20 2010-09-09 Othera Holding, Inc. Amelioration of macular degeneration and other ophthalmic diseases
JP2008528702A (ja) * 2005-02-02 2008-07-31 ミトス・ファーマシューティカルズ・インコーポレーテッド 免疫疾患の治療又は予防において使用するためのニトロキシド類
US20090042937A1 (en) * 2005-02-02 2009-02-12 Louis Habash Nitroxides for use in treating or preventing amyloid-related diseases
JP2008528694A (ja) 2005-02-02 2008-07-31 ミトス・ファーマシューティカルズ・インコーポレーテッド 糖尿病の治療または予防において使用するためのニトロキシド類
US20080312283A1 (en) * 2005-05-26 2008-12-18 Othera Pharmaceuticals, Inc. Use of Hydroxylamine Derivates for Inhibiting Vitrectomy-Induced Cataracts
AU2006279951B2 (en) * 2005-08-11 2013-02-14 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for determining redox status of a tissue
EP1933941A2 (de) 2005-08-25 2008-06-25 Philip R. Houle Behandlungssysteme zur abgabe von sensibilisatorlösungen
US7538130B2 (en) * 2005-09-26 2009-05-26 Basf Corporation Hindered amine light stabilizer, methods of making, and compositions
US20070160642A1 (en) * 2006-01-12 2007-07-12 Pacetti Stephen D Implantable medical devices coated with a polymer-bound superoxide dismutase mimic
US20070197599A1 (en) * 2006-02-02 2007-08-23 Matier William L Hydroxylamines and derivatives as anti-angiogenic agents
US20070203190A1 (en) * 2006-02-22 2007-08-30 Ghanshyam Patil Hydroxylamines and derivatives for the inhibition of complement activation
US20070197593A1 (en) * 2006-02-22 2007-08-23 Matier William L Hydroxylamines and derivatives for treatment of inflammatory conditions of the liver
US20080032990A1 (en) * 2006-07-07 2008-02-07 Khalifah Raja G Inhibitors of advanced glycation end products
US20100041716A1 (en) * 2006-11-29 2010-02-18 Mitos Pharmaceuticals, Inc. Nitroxides for use in treating or preventing hypercholesterolemia
US20080200405A1 (en) * 2007-02-16 2008-08-21 Ghanshyam Patil Drug Resistance Reversal In Neoplastic Disease
JP2010520888A (ja) * 2007-03-09 2010-06-17 アメリカ合衆国 神経変性の治療としてのニトロキシドラジカル
US7820963B2 (en) * 2007-08-06 2010-10-26 Metabolic Alayses, Inc. Method for generation and use of isotopic patterns in mass spectral data of simple organisms
WO2009026579A1 (en) * 2007-08-23 2009-02-26 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
US8859235B2 (en) 2009-08-14 2014-10-14 Basf Se Methods in cell cultures, and related inventions, employing certain additives
US20110130421A1 (en) * 2009-10-29 2011-06-02 Georgetown University Methods and Compositions for the Treatment of Chronic Renal Hypertension
WO2012110435A1 (en) * 2011-02-14 2012-08-23 Basf Se Bio process additives
US20130224281A1 (en) * 2011-04-07 2013-08-29 United States Of America As Represented By The Administrator Of The National Aeronautics & Space Method and composition for ameliorating the effects for a subject exposed to radiation or other sources of oxidative stress
WO2015139034A1 (en) * 2014-03-14 2015-09-17 The General Hospital Corporation System and method for imaging free radicals
US10231959B2 (en) 2016-03-23 2019-03-19 Louis Habash Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
US20180078539A1 (en) 2016-03-23 2018-03-22 Louis Habash T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide
CA3149383A1 (en) 2019-08-01 2021-02-04 Praetego, Inc. Inhibitors of advanced glycation end products

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988005044A1 (en) * 1986-12-29 1988-07-14 Pharmacia Ab Nitroxide compounds for the preparation of a pharmaceutical composition intended for the prophylaxis and treatment of ischemic cell damage
AU1362488A (en) * 1987-01-28 1988-08-24 Peter H. Proctor Topical composition and method for stimulating hair growth with stable free radicals

Also Published As

Publication number Publication date
EP0787492B1 (de) 2003-09-17
WO1991013619A1 (en) 1991-09-19
ES2207690T3 (es) 2004-06-01
EP0520005A1 (de) 1992-12-30
AU644865B2 (en) 1993-12-23
DE69127437D1 (de) 1997-10-02
EP0520005B1 (de) 1997-08-27
ATE249829T1 (de) 2003-10-15
JP2741427B2 (ja) 1998-04-15
CA2078287C (en) 1996-11-26
AU7542391A (en) 1991-10-10
ATE157249T1 (de) 1997-09-15
DE69133313T2 (de) 2004-07-01
US5462946A (en) 1995-10-31
DK0787492T3 (da) 2004-02-02
EP0787492A1 (de) 1997-08-06
CA2078287A1 (en) 1991-09-17
EP0520005A4 (en) 1993-04-21
DE69133313D1 (de) 2003-10-23
JPH05501114A (ja) 1993-03-04

Similar Documents

Publication Publication Date Title
DE69127437T2 (de) Stickoxide zur gewichtsreduktion
NO990542D0 (no) K-252a-derivater og anvendelse av K-252a-derivater
FI931406A0 (fi) Foerfarande foer framstaellning av lineariskt polyeten med laog taethet
NO934304L (no) Fremgangsmaate for behandling av fluoralumosilikatglass
DE69120351D1 (de) Vorwärtsgekoppelter Verstärker
DE69326496D1 (de) Ringförmige Röntgenstrahlenquelle
DE69126341D1 (de) Elektrotherapeutische Einrichtung
NO912158L (no) Fremgangsmaate for behandling av en undergrunnsformasjon
NO894845D0 (no) Fremgangsmaate og materialer for mikrobiell bioomdannelse av toluen og andre fenylforbindelser.
DK0642506T3 (da) Heterocyclisk disubstituerede sulfonaminocarbonylforbindelser
NO171798C (no) Fremgangsmaate for behandling av sinkholdige biprodukter og avfallsmaterialer
NO914577D0 (no) Fremgangsmaate for fremstilling av heterocyklisk substituerte piperazinoalkylbenzoksazin- og -tiazinforbindelser
NO922315D0 (no) Sproeyte for tilfoersel av medisin
SE9101464D0 (sv) Anordning foer eliminering av moebelhaelta
FI923360A (fi) Foerfarande foer framstaellning av dimetylacetoacetamid
KR890701106A (ko) 과지혈증의 치료를 위한 옥소퀴나졸린 유도체의 용도
SE8400993D0 (sv) Sett och anordning for behandling av bredemnen i sagverk
NO171565C (no) Fremgangsmaate for behandling av manganslam
FI913414A (fi) Foerfarande foer framstaellning av 2-hydroxi-3-halogen-5-nitropyridiner.
IT8819472A0 (it) Apparecchiatura per il trattamento di materiali sensibili.
SE9003019D0 (sv) Anordning foer underlaettande av handskandet med handlingar i mappar
SE9101717D0 (sv) Saett och anordning foer haeftning
SE9002209D0 (sv) Anordning foer laengdmatning av traedstammar
IT9051204V0 (it) Piumotto sfoderabile per passeggino o carrozzina
SE8505324D0 (sv) Sett och anordning for behandling av gas

Legal Events

Date Code Title Description
8364 No opposition during term of opposition